I2TN
Loos
About I2TN
Utilisation d’anticorps à domaine simple ou nanobodies pour l’immunothérapie dans les tauopathies
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Last round: Non-Equity Assistance (Jun 2020)
- Website: i2tn.com
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/i2tn-578853 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.